{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,28]],"date-time":"2025-10-28T05:47:18Z","timestamp":1761630438601},"reference-count":15,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2007,1,12]],"date-time":"2007-01-12T00:00:00Z","timestamp":1168560000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Clin Rheumatol"],"published-print":{"date-parts":[[2007,9,14]]},"DOI":"10.1007\/s10067-006-0521-x","type":"journal-article","created":{"date-parts":[[2007,1,11]],"date-time":"2007-01-11T08:08:30Z","timestamp":1168502910000},"page":"1783-1785","source":"Crossref","is-referenced-by-count":15,"title":["Tumor necrosis factor blockade in the management of children with orphan diseases"],"prefix":"10.1007","volume":"26","author":[{"given":"Riva","family":"Brik","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vardit","family":"Gepstein","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eli","family":"Shahar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dorit","family":"Goldsher","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Drora","family":"Berkovitz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2007,1,12]]},"reference":[{"key":"521_CR1","unstructured":"Magnani A, Palmisani E, Sala I et al (2005) Review for the Generalist: Update on biologic therapies for pediatric rheumatic diseases. PROJ. Available at http:\/\/Pedrheumonlinejournal.org\/july-August05\/Biologics.htm"},{"key":"521_CR2","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1136\/ard.2004.028498","volume":"63","author":"EC Keystone","year":"2004","unstructured":"Keystone EC (2004) The utility of tumor necrosis factor blockade in orphan diseases. Ann Rheum Dis 63:79\u201383","journal-title":"Ann Rheum Dis"},{"key":"521_CR3","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1056\/NEJM200003163421103","volume":"342","author":"DJ Lovell","year":"2000","unstructured":"Lovell DJ, Giannini EH, Reiff A et al (2000) Etanercept in children with polyarticular juvenile rheumatoid arthritis. New Engl J Med 342:763\u2013767","journal-title":"New Engl J Med"},{"key":"521_CR4","doi-asserted-by":"crossref","first-page":"1671","DOI":"10.1001\/jama.294.13.1671","volume":"294","author":"PJ Hashkes","year":"2005","unstructured":"Hashkes PJ, Laxer RM (2005) Medical treatment of juvenile idiopathic arthritis. JAMA 294:1671\u20131684","journal-title":"JAMA"},{"key":"521_CR5","doi-asserted-by":"crossref","first-page":"2103","DOI":"10.1002\/art.21121","volume":"52","author":"SM Tse","year":"2005","unstructured":"Tse SM, Burgos-Vargas R, Laxer RM (2005) Anti-tumor necrosis factor alpha blockade in the treatment of juvenile spondyloarthropathy. Arthritis Rheum 52:2103\u20132108","journal-title":"Arthritis Rheum"},{"key":"521_CR6","first-page":"1241","volume":"31","author":"OS Nakamura","year":"2004","unstructured":"Nakamura OS, Shimakawa HS, Kawashima M et al (2004) Efficacy, safety, and pharmacokinetics of multiple administration of infliximab in Bechet\u2019s disease with refractory uveoretinitis. J Rheumatol 31:1241\u20131243","journal-title":"J Rheumatol"},{"key":"521_CR7","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1053\/sarh.2003.50022","volume":"33","author":"DG Stokes","year":"2003","unstructured":"Stokes DG, Kremer JM (2003) Potential of tumor necrosis factor neutralization strategies in rheumatologic disorders other than rheumatoid arthritis. Semin Arthritis Rheum 33:422\u2013423","journal-title":"Semin Arthritis Rheum"},{"issue":"Suppl 1","key":"521_CR8","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/j.semarthrit.2005.01.003","volume":"34","author":"B Haraoui","year":"2005","unstructured":"Haraoui B (2005) Differentiating the efficacy of the tumor necrosis factor inhibitors. Semin Arthritis Rheum 34(Suppl 1):7\u201311","journal-title":"Semin Arthritis Rheum"},{"key":"521_CR9","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1016\/j.jpeds.2004.06.046","volume":"145","author":"S Ozen","year":"2004","unstructured":"Ozen S, Anton J, Arisoy N et al (2004) Juvenile polyarteritis: results of a multicenter survey of 110 children. J Pediatr 145:517\u2013522","journal-title":"J Pediatr"},{"key":"521_CR10","first-page":"1371","volume":"32","author":"J Al-Bishri","year":"2005","unstructured":"Al-Bishri J, le Riche N, Pope JE (2005) Refractory polyarteritis nodosa successfully treated with Infliximab. J Rheumatol 32:1371\u20131373","journal-title":"J Rheumatol"},{"key":"521_CR11","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1016\/S0140-6736(97)09408-7","volume":"351","author":"E Ben-Chetrit","year":"1998","unstructured":"Ben-Chetrit E, Levy M (1998) Familial Mediterranean fever. Lancet 351:659\u2013664","journal-title":"Lancet"},{"key":"521_CR12","doi-asserted-by":"crossref","first-page":"1416","DOI":"10.1002\/1529-0131(200106)44:6<1416::AID-ART236>3.0.CO;2-6","volume":"44","author":"R Brik","year":"2000","unstructured":"Brik R, Shinawi M, Kasinetz L, Gershoni-Baruch R (2000) The musculoskeletal manifestations of familial Mediterranean fever in children genetically diagnosed with the disease. Arthritis Rheum 44:1416\u20131419","journal-title":"Arthritis Rheum"},{"key":"521_CR13","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1002\/art.20920","volume":"53","author":"S Daysal","year":"2005","unstructured":"Daysal S, Ackil G, Goker B et al (2005) Infliximab therapy in a patient with familial Mediterranean fever and chronic hip replacement (letter). Arthritis Rheum 53:146\u2013148","journal-title":"Arthritis Rheum"},{"key":"521_CR14","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1378\/chest.124.1.177","volume":"124","author":"JP Utz","year":"2003","unstructured":"Utz JP, Limper AH, Karka S et al (2003) Etanercept for the treatment of stage II and III progressive pulmonary sarcoidosis. Chest 124:177\u2013185","journal-title":"Chest"},{"key":"521_CR15","doi-asserted-by":"crossref","first-page":"2028","DOI":"10.1378\/chest.124.5.2028","volume":"124","author":"SD Roberts","year":"2003","unstructured":"Roberts SD, Wilkes DS, Burgett RA, Knox KS (2003) Refractory sarcoidosis responding to infliximab. Chest 124:2028\u20132031","journal-title":"Chest"}],"container-title":["Clinical Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10067-006-0521-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s10067-006-0521-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10067-006-0521-x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,5,29]],"date-time":"2019-05-29T08:51:05Z","timestamp":1559119865000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s10067-006-0521-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2007,1,12]]},"references-count":15,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2007,9,14]]}},"alternative-id":["521"],"URL":"https:\/\/doi.org\/10.1007\/s10067-006-0521-x","relation":{},"ISSN":["0770-3198","1434-9949"],"issn-type":[{"value":"0770-3198","type":"print"},{"value":"1434-9949","type":"electronic"}],"subject":[],"published":{"date-parts":[[2007,1,12]]}}}